Objective. To perform a thorough assessment of the recently published Mint Trials in order to illustrate how to read and analyze a study critically, according to principles of evidence-based medicine.
Background
Guidelines for composing and assessing a paper on the treatment of pain were recently published [1] that describe the critical components of a high-quality manuscript that allows communication of all relevant information from authors to readers. These guidelines, in a step-by-step manner, discuss the core principles and practical application of evidence-based medicine (EBM). In addition to the mentioned publication, a similar set of EBM principles is taught in the Spine Intervention Society (SIS) EBM course curriculum, which consists of EBM I: Accreditation Course in Assessing Studies of Treatment, and EBM II: Accreditation Course in Assessing Studies of Diagnostic Tests and Strategies. Graduates from these EBM courses are subsequently invited to practice and apply these principles in the format of a scientific journal club group discussion, EBM III. In this setting, EBM course graduates have the opportunity to appraise and discuss selected publications with their peers and experts in the field of spine care. Critical discourse, in this type of forum, is valuable for prospective authors of scientific manuscripts. It is equally valuable for clinicians learning to appraise clinical studies in order to determine when and how to incorporate new evidence into clinical practice and discuss this evidence with patients and colleagues.
Many clinicians are not able to attend the EBM courses and do not have the opportunity to critically apply EBM principles to selected publications in an expert-peer journal club setting. Here, we apply the published guidelines [1] to a recently published article describing a large study that claimed its "findings do not support the use of radiofrequency denervation to treat chronic low back pain" [2] . This study might be of concern to readers. Therefore, we have chosen to use this study as an example of how to assess published studies. We do so both to show untutored readers how to read a study perceptively and to demonstrate how training in EBM provides readers with the skills to do so.
EBM Assessment of the Mint Randomized Clinical Trials

Introduction
The objective of the Mint Trials was to determine whether RFN in addition to a standardized exercise program is more effective than a standardized exercise program alone for the treatment of chronic low back pain (CLBP). The authors justify the relevance of this study question by discussing the frequent utilization of RFN despite mixed support for the effectiveness of this procedure in the medical literature. Indeed, the quality of published studies that evaluate RFN effectiveness varies, and in many cases, it may not adhere to EBM standards. However, the authors of the Mint Trials neither discuss the known methodological shortcomings of the medical literature on RFN nor explain how their study would address these shortcomings; such background information would have helped the reader to better understand the rationale for their specific study methodology. The authors do clarify that the Mint Trials were intended to test "patient selection and interventions as performed in Dutch daily practice." [3, 4] . As the Dutch daily practice differs substantially from the standard RFN selection and intervention technique as described in the SIS guidelines [3, 5, 6] , the results of the Mint Trials do not apply to standard RFN patient selection and treatment. Unfortunately, this important clarification was published several months after the original research article and not as an article addendum; thus, this truth may not be apparent to many who read only the original publication.
The Mint Trials compared the effectiveness of two treatment protocols that are expected to provide a therapeutic effect. As such, the study meets the definition of a pragmatic randomized comparative trial; however, the question posed in the Mint Trials is not pragmatic at all. In order to be generalizable, a pragmatic trial must compare treatments that represent realistic options in clinical practice. If one of the study treatments cannot be applied in the same manner in a real-world setting, the study fails to provide useful insights. Unfortunately, this is the case with the question posed by the authors. In the real world, patients are typically considered appropriate candidates for RFN only if they have already not responded to a structured exercise or physical therapy (PT) program. Thus, in reality, patients do not face the choice of the treatment options presented in the Mint Trials. Therefore, we must view this study as having the potential to answer a theoretical question with very little, if any, pragmatic value.
Study Aim
The aim of the study was to determine whether RFN, in addition to a standardized exercise program, is more effective than a standardized exercise program alone for the treatment of CLBP. However, CLBP represents a symptom of heterogeneous etiologies, rather than a diagnosis, and is not appropriate for a target-specific intervention like RFN unless a treatable source of pain has been accurately identified. Investigating treatment based on a symptom, instead of an accurate diagnosis, can be illustrated by a hypothetical study designed to evaluate the effectiveness of an antibiotic for cough. Like CLBP, cough has many potential causes. These include bacterial pneumonia that is expected to respond to antibiotics, tumors, foreign bodies, asthma, and many other diagnoses that nobody expects to respond to antibiotic therapy. Thus, a study of antibiotic treatment for cough that does not first accurately identify the cause of the patient's cough will most likely fail to show that antibiotics are ineffective for the treatment of cough. Even worse, concluding from this study that antibiotics are not supported to treat anyone with a cough would be problematic for individuals with bacterial pneumonia.
Although the Mint Trials describe an attempt to identify the cause of CLBP in the study population, the true source of CLBP remains unclear due to both improper inclusion criteria and inadequate diagnostic methods, as will be discussed in more detail below.
Methods
Study Design, Funding
Juch et al. report on the results of four different nonblinded, prospective, comparative randomized trials conducted at 16 pain centers in the Netherlands. One trial that included presumed discogenic low back pain was prematurely discontinued due to inability to recruit participants. The three other trials aimed to address chronic low back pain that originated from (1) zygapophyseal "facet" joints, (2) sacroiliac joints (SIJs), and (3) a combination of facet joints, SIJs, and/or intervertebral discs. Study disclosures recognize grants from the Netherlands Organization for Health Research and Development, the Dutch Society for Anesthesiology, and the Dutch health insurance companies. Funding from an insurance company represents a potential conflict of interest that should be considered in the interpretation of the study results and conclusions.
Inclusion Criteria-Demographic
The Mint Trials excluded patients older than 70 years of age. The reason is not stated, but this introduces sample bias into this study. Patients >70 years old commonly suffer from low back pain of sacroiliac, discogenic, or facetogenic origin [7] . In particular, the prevalence of facetogenic pain is far higher in individuals >70 years of age, while discogenic pain is more common in the younger population [7] .
Inclusion Criteria-Diagnostic Categorization
In order to distinguish facetogenic and SIJ-mediated pain from other potential sources of CLBP, the Mint Trials would have ideally implemented a diagnostic test protocol with the best-known validity and reliability. However, the Mint Trials used diagnostic criteria with significantly inferior diagnostic capability, allowing many potential subjects without the index condition to be enrolled and randomized. Specifically, facetogenic pain was diagnosed if a minimum threshold of 50% pain reduction was achieved at 30-90 minutes following a single diagnostic medial branch nerve (MBN) block. The methods do not state a requirement for the duration of pain relief, which is important for the correct interpretation of the result of a diagnostic block. Even in studies that use a minimum threshold of 50% pain reduction and require relief of pain for the duration of action of the local anesthetic used for the block, the false positive rate remains prohibitively high, ranging from 25% to 45% [8] . Further, pain relief alone is an insufficient criterion for defining a positive block; the patient must also demonstrate improved function during movements or activity previously hampered by pain [5] . For example, a patient may report pain reduction following a diagnostic block because he/she is seated in a comfortable recliner that diminishes pain, rather than because the block provided temporary anesthesia of the structure responsible for pain.
These above steps help to reduce the likelihood of a false positive block, yet false negative blocks are also of concern. In the Mint Trials, prior to MBN block, intravascular needle placement was not ruled out with contrast injection under live fluoroscopic observation. This increased the likelihood of a false negative diagnosis by up to 11% [9] and resulted in the potential exclusion of individuals with true facetogenic pain who might benefit from RFN treatment. These concerns regarding diagnostic standards and accuracy are further enhanced by the anatomic levels of treatment provided to the study participants. Specifically, every Facetogenic Pain Trial participant underwent bilateral L3/L4, L4/5, and L5/S1 RFN procedures. This means that of 509 participants who underwent diagnostic MBN blocks, not a single individual was diagnosed with a unilateral or more localized source of pain.
All of this suggests a lack of diagnostic accuracy in the Mint Trials, and that the Facetogenic Pain Trial targeted patients with diffuse, nonspecific CLBP, rather than patients with localized pain originating from the facet joints. Indeed, further evidence from the Mint Trials supports this interpretation. The reported "positive" response rate to diagnostic MBN blocks was surprisingly high (72%), a number that greatly exceeds the known 10-45% prevalence of lumbar facet joint pain in people with CLBP [10] [11] [12] [13] [14] [15] [16] . As the enrollment rate for individuals who underwent MBN blocks was much higher than expected, given the known prevalence of lumbar facet joint pain, the Facetogenic Pain Trial population likely includes many individuals without facetogenic pain.
In order to diagnose SIJ-mediated pain, the Mint Trials implemented criteria similar to the Facetogenic Pain Trial to interpret the SIJ diagnostic block response. A singlesite, single-depth lateral branch nerve (LBN) block technique was used. The authors refer to the SIS guidelines to justify use of this technique, yet the SIS guidelines neither recommend nor mention this method. Indeed, single-site, single-depth LBN blocks demonstrate inferior diagnostic validity compared with multisite, multidepth LBN blocks [17] .
Participants in the Combination Pain Trial were included based solely on history and physical examination findings, which are unreliable for diagnosing a specific anatomic source of CLBP [15] , as is the prerequisite to any targeted invasive treatment. These participants then underwent a sequence of diagnostic blocks, but logic to justify the order of blocks is not elucidated, and it remains unclear how discogenic pain was diagnosed. Many participants likely received incorrect treatments based on these ill-defined screening methods.
Given these inclusion criteria, we cannot be confident that participants in the Mint Trials did, in fact, have facetogenic pain, SIJ-mediated pain, discogenic pain, or any combination thereof. In the text that follows, for ease of reading, we maintain the nomenclature used by the authors to describe the three trial populations, yet it must be reinforced that the true source of CLBP in each of these three trials is not clear.
Study Interventions-RFN Group
In the management of CLBP, once the correct diagnosis is established, it is equally vital that an appropriate treatment technique is applied. Anatomic studies demonstrate greater likelihood of target nerve capture within the RFN lesion volume when the RFN electrode is placed in parallel, rather than perpendicular, to the MBN [18] [19] [20] . This is a result of the geometry of the radiofrequency lesion. Ex vivo tissue studies show that conventional RFN electrodes coagulate tissue in a radius around the exposed tip with minimal distal extension [21] . Thus, when the RFN electrode is placed in parallel to the MBN, this maximizes the chance that the coagulation radius will include the nerve. As the orientation of the electrode is rotated away from parallel, the chance of capturing the MBN within the effective coagulation radius diminishes, and it is least in the perpendicular position. Further, even if the nerve were captured by nonparallel electrode placement, the segment of nerve interrupted would be shorter than when parallel electrode placement is used [18] . The findings of these anatomic and ex vivo tissue studies are reflected in the clinical outcome literature. For example, studies demonstrate high success rates and long duration effects when treatment protocols require use of large-gauge radiofrequency electrodes (which create large lesion volume) [21] that are placed in parallel to the target MBNs [22] . In contrast, the RFN protocol used in the Mint Trials included a small, 22-gauge electrode (which creates a small lesion) [21] , and the protocol does not mention use of parallel electrode placement. Fluoroscopic images were not provided; therefore, the readers cannot assess the adequacy of the RFN technique used. Further, the Mint study protocol states that images of the MBN RFN procedures "will be submitted to an expert panel to assess correct needle placement" (Appendix B), yet this information was not published. Thus, there is a high likelihood that facet joint denervation was not accomplished or only partially completed in a significant proportion of participants in the Mint Trials, given both the unknown orientation of RFN probe placement and the use of small-gauge electrodes.
In the SIJ-mediated Pain Trial, the investigators used heterogeneous techniques to denervate the LBNs: cooled RFN, Palisade RFN technique, and an RFN technique involving the Simplicity III device. While clinical efficacy has been demonstrated in a sham-controlled trial of cooled RFN using specific electrode placement at the L5 dorsal ramus and encircling the S1-S3 foramina [23] , LBN RFN using the Palisade technique and Simplicity III technique have not been validated with the same degree of experimental rigor. Further, one study found that LBN RFN with Simplicity III was associated with inferior clinical outcomes compared with the use of the cooled RFN technique [24] . Thus, Mint Trial participants who received LBN RFN did not necessarily receive equal treatments. In order to establish LBN RFN effectiveness, different techniques should be evaluated separately rather than grouped.
Similarly, in the Combination Pain Trial, the investigators used heterogeneous techniques to denervate the annulus fibrosis of the intervertebral discs. These techniques included both biacuplasty and intradiscal electrothermal therapy. Both of these treatments produce some beneficial effects in a carefully selected patient population, requiring application of much more stringent diagnostic criteria than were used in the Mint Trials [25, 26] . Again, in order to establish intradiscal RFN effectiveness, specific techniques should be evaluated separately rather than grouped.
Study Interventions-Both Groups
Both groups in all of the Mint Trials received a standardized exercise program: one group received RFN and exercise while the other group received exercise only. The study protocol states that participants received a program based on Dutch physical therapy guidelines, but there is no description of the frequency, duration, or intensity of sessions received in the two groups. Only the dropout rate is provided. Better description and characterization of the exercise treatments are necessary to compare between groups, so that readers could be confident that both groups in each trial received similar PT interventions. The authors also do not report what PT or exercise program(s) participants had already received prior to study enrollment. Based on the Dutch system, it is easy to imagine that some of the study participants had already tried and failed various PT or exercise treatments, while others had not. This scenario introduces the potential for significant difference in exercise treatment experience and expectations between the study groups. Because this information is not provided to the reader, a selection bias cannot be excluded.
An additional detail regarding the characterization of study interventions must be highlighted. All participants in the Facetogenic Pain Trial and the SIJ-mediated Pain Trial received diagnostic blocks regardless of the treatment group to which they were randomized. Therefore, these two trials actually compared anesthetic block and RFN and exercise to anesthetic block and exercise. Anesthetic blocks can affect pain intensity for a duration exceeding that expected by the local anesthetic used [27] . This confounding treatment effect could have been accounted for by excluding participants from the study if the diagnostic blocks resulted in prolonged pain reduction; however, this was not described in the study protocol.
Co-interventions
All three Mint Trials allowed co-interventions after three months. These included new medication prescriptions, RFN, and even surgery. In the exercise-only group, 25%, 35%, and 31% of participants underwent RFN in the Facetogenic Pain, SIJ-mediated Pain, and Combination Pain Trials, respectively. In the context of this study, RFN represents "cross-over" rather than "cointervention," as RFN is the only added treatment provided in the experimental group. However, the results of RFN cross-over treatment were not included in the data analyses at the six-, nine-, and 12-month assessments. It is important to contrast this so called "as-treated analysis" with the standard intention-to-treat analysis in studies with significant cross-over. Beyond RFN treatment in the non-RFN group, the co-interventions received by participants in either group were not described. According to the study protocol, they could have included spinal or sacroiliac joint fusion procedures. Therefore, the data reported after the threemonth assessment are not necessarily representative of the stated study treatments.
Psychological support was an additional co-intervention allowed at any time point. This intervention was provided "when necessary." The authors do not disclose how many participants received psychological support or how much they received. Thus, it is not possible to assess the relative treatment effect of this cointervention or to determine whether one study group received comparatively more psychological support than the other group. Thus, another potential source of study bias remains unknown to the reader.
Outcome Measurement
The Mint Trials used validated patient-reported outcome measures that are specific to CLBP. Other useful measures, not used, include medication use, return to work, additional health care utilization, and health care costs. While the content of the outcome assessment battery was appropriate, a premature primary end point of three months was selected. This time point is problematic for a few reasons. First, it masks the influence of crossover and co-interventions allowed beyond it. Second, by the nature of its mechanism, RFN is intended for longterm pain relief, and accordingly, three-month outcomes are a poor predictor of long-term success [28] . In regard to the mechanisms of benefit, RFN does not simply sever target nerves, but rather, results in coagulation of proteins in situ [21] . Thus, instead of nerve regeneration following Wallerian Degeneration as with severed nerves, restoration of afferent pain signaling following RFN is delayed by slow endocellular mechanisms required to clear damaged proteins [5, 29] . As such, RFN is used as a long-term treatment modality when disruption of afferent pain signaling is desired. Indeed, when performed in appropriately selected patients and with a validated technique, RFN results in clinically meaningful improvement in pain for at least six to 12 months or longer [22, 30] . Therefore, a study designed to assess the clinical effectiveness of RFN should use a minimum primary end point of six months. Allowing cross-over earlier is acceptable, but only if an as-treated analysis is emphasized in the presentation of treatment outcomes data.
Power Analysis
The power analysis estimates for the three Mint Trials were based on an intergroup difference of two points on the numerical rating scale (NRS) for pain intensity, based on the minimally clinically important difference (MCID) for CLBP. This is not an appropriate application of the MCID standard. The MCID is an assessment of the minimum change from baseline, and not intended as a measure of the necessary magnitude of differences between groups, as emphasized in the Mint Trials. It is more appropriate to use the MCID to compare between groups the proportion of participants who achieve the pre-to-post-treatment MCID threshold, or to compare if the two groups' pre-to-post-treatment mean change in pain either achieved or failed to achieve this MCID threshold. The impact of this difference in the use of the MCID on the outcomes reported is discussed in further detail below.
Data Analysis
The primary analysis was based on group means rather than categorical responder analysis, the latter being more appropriate in studies designed to assess the treatment of pain [1, 31] . Further, in the secondary categorical analysis, a worst-case scenario analysis was not applied. Worst-case scenario analysis accounts for patients lost to follow-up, rather than removing them from the data set, thus preventing an overestimation of the treatment response. We present a corrected categorical data analysis in Table 1. As detailed above, an intention-to-treat analysis was applied, yet many participants did not receive the treatment to which they were allocated. In fact, 36 participants (35%) allocated to the RFN group in the Combination Pain Trial did not receive RFN. Thus, because an as-treated analysis accounting for protocol violations is not included in the primary analysis and is not shown for comparison in the primary article, the reader is potentially misled about the effectiveness of the stated treatment in both study groups in each trial.
The study outcomes were not stratified to account for potentially confounding factors. As previously discussed, different methods of LBN RFN were used, but outcomes were not stratified by method. Outcomes in the exercise-only group of each trial were not stratified by the "dose" (i.e., frequency, duration, intensity) of therapy received or by completion of the PT protocol vs dropout. Such stratification within each group would have allowed the reader to determine if a similar dose of exercise was received in a similar proportion of participants Practical Application of Evidence-Based Medicine Principles in both the RFN and exercise-only groups within each trial. The same lack of transparency regarding the psychological support co-intervention (number of participants and frequency/amount of treatment) limits the reader's ability to assess the potential treatment effect as well as potentially unequal treatment effects if intergroup differences were present.
Results
Screening, Enrollment, and Dropout/Exclusion
As previously discussed, the Mint Trials were intended as pragmatic studies. However, a minority of the 10,592 potential participants with CLBP were not included. A total of 5,168 were enrolled into an observational arm, yet it is not stated why they were deemed inappropriate for the randomized trials. The 5,424 remaining participants were considered suitable for the trials and asked to enroll, with only 12% (6% of those screened) being randomized. Of the patients in the Facetogenic Pain and SIJ-Mediated Pain Trials who were asked to participate, 62% declined with no reason provided. Thus, the study sample has a high risk of bias and is not likely to represent a realistic clinical population.
Study Sample Characteristics
Examination of the study sample characteristics reveals that the majority of demographic factors were similar between groups in each trial. However, the RFN group in all three trials had a longer median duration of pain at the time of study enrollment compared with the exercise-only group (e.g., 140 vs 100 months for the Facet Joint Trial). Duration of pain prior to treatment is a known factor that predicts a reduced likelihood of treatment response in patients with chronic pain conditions [32] [33] [34] [35] [36] . A study cohort with a median chronic pain duration greater than 12 years is unlikely to contain a high proportion of participants likely to experience a successful outcome following RFN.
The study sample information does not include the number of patients in each group who had already received PT or an exercise program prior to enrollment. Participants who had not received PT or an exercise program prior to study enrollment may have had variable potential to respond to the study treatment(s). Thus, while heterogeneity was likely present in this respect, the reader cannot determine how it may have affected treatment outcomes.
Loss to Follow-up
Loss to follow-up was significant beyond three months. Forty-one percent of participants were lost to follow-up in the complete data set. However, this is irrelevant as outcomes beyond three months are not meaningful in the Mint Trials given that co-interventions were allowed, as previously discussed.
Presentation of Outcome Data
Raw data are not published, so the reader is unable to replicate full statistical analyses. However, using the investigators' definitions of clinical success, the categorical analysis can be corrected to include a worst-case scenario analysis, as shown in Table 1 . The proportion of responders was significantly larger in the RFN group compared with the exercise-only group in all three trials when using the global pain reduction (GPR) definition of treatment success, and in both the SIJ-mediated Pain and Combination Pain Trials when using both !30% NRS reduction and an NRS reduction of two or more points as the definition of treatment success (P < 0.05). Notably, we cannot subtract the participants who were included in the RFN groups but did not have RFN as the success vs failure within this subgroup is not published. However, it is likely that the treatment effects seen in the RFN groups are attenuated as a result, especially in the Combination Pain Trial, where 35% of participants assigned to receive RFN did not undergo this treatment. It is also notable that the authors do not include categorical data with regard to function (Oswestry Disability Index), so success rates with respect to improvements in physical function cannot be calculated.
Additionally, not all patients completed the standardized exercise program. In the Facet Pain Trial, only 101 (81%) of 125 participants in the RFN group completed the exercise program, and only 92 (73%) of 126 participants in the exercise-only group completed the program. Similarly, in the SIJ-mediated Pain Trial, only 89 (77%) of 116 participants in the RFN group and 69 (62%) of 112 participants in the exercise-only group completed the program. It is notable that more participants in the RFN group completed the exercise program, and the reader is left to speculate: Did RFN allow more participants to tolerate and subsequently complete the exercise program?
Discussion
Authors' Conclusions from the Study Data
A cornerstone to the authors' conclusions is the use of the minimal clinically important difference for low back pain of at least 2.0 points on the NRS [37] . In the Facet Joint Trial, subjects in the exercise group showed a mean NRS pain score reduction from 7.1 to 5.4 at three months (mean difference ¼ 1.7), whereas subjects in the treatment group showed a mean NRS pain score reduction from 7.1 to 5.0 at three months (mean difference ¼ 2.1). An appropriate interpretation of these results would acknowledge that the improvement observed in the treatment group (2.1) surpassed the Ostelo MCID threshold, while the improvement observed in the exercise group did not reach this threshold. Therefore, exercise therapy alone does not achieve clinically significant improvement in back pain. Instead of stating this conclusion, the authors calculated the difference of the differences for unclear reasons, and as the incremental contribution of radiofrequency denervation over exercise alone is 0.4 on the NRS (2.1 as opposed to 1.7), they concluded that RFN did not result in a clinically significant improvement in pain. This use of MCID is unusual and incorrect. The methodological literature is unambiguous about the correct usage of MCID. In the original publication, Ostelo et al. [37] cautioned that "proposed [MCID] values [are] for individual rather than group changes." The US Food and Drug Administration, in developing guidance for industry on patient-reported outcomes, warned that the "group average is not an appropriate threshold for individual change" [38] . A use of the MCID is to perform a "responder analysis" using the change within study participants longitudinally, with a subsequent comparison between trial groups of the proportion of subjects who experience more than a 2.0-point pain reduction from baseline to three months.
Indeed, the authors' conclusions are directly opposed by a corrected analysis that employs the recommended categorical analysis for spine treatment outcomes research and the appropriate interpretation of the MCID threshold. This corrected analysis demonstrates that a significantly larger proportion of participants reported a successful outcome in the RFN group compared with the exercise-only group in all three trials (Table 1, Figure 1 ), and only the groups receiving RFN reached the MCID threshold of clinically important improvement (NRS > 2) in all three trials at the target three-month assessment (Table 2) , thus satisfying the primary outcome proposed in the study methods for treatment with RFN and exercise, but not for exercise alone. The authors proceed to conclude, "Based on this study, radiofrequency denervation is not recommended and should be performed only in a research setting." However, this statement is inconsistent with the corrected analysis of the study data (Tables 1 and 2, Figure 1 ). The correct interpretation of these results is to state, 'Exercise does not achieve a statistically significant and clinically meaningful reduction in pain unless combined with RFN.'
In addition to misinterpreting the study data, the authors misrepresent their findings by failing to specifically state in their conclusions that these results apply only to the Dutch RFN practice-a practice that differs substantially from the standard RFN practice that is described in the SIS guidelines. In brief, the Mint Trials involved a sample of patients with an unclear source of CLBP who received RFN using insufficient techniques for successful neurolysis.
Comparison with Similar Literature
While the authors do compare their results with other studies of RFN, they only refer to literature that used flawed selection protocols and/or procedure techniques without any discussion of these shortcomings. They do not compare their outcomes with the RFN studies that used validated diagnostic standards to select patients and employed adequate procedural techniques to optimize the likelihood of successful neurolysis [22, 30] . Such a comparison would have revealed the inferiority of the patient selection and treatment techniques used in the Mint Trials compared with validated standards.
Summary of Major Points
The Mint Trials, partially funded by Dutch insurance companies, studied patients with unclear sources of chronic low back pain that were not representative of a realistic clinical population of appropriate candidates for RFN. It is not clear if patients had already received the control treatment (PT or an exercise program) prior to enrollment in the study. The diagnostic criteria used were insufficient to identify the true cause(s) of chronic low back pain in the study population. The study interventions included single anesthetic blocks in the groups allocated to RFN as well as the groups allocated to Figure 1 Methodological error present in the Mint Trials and the subsequent analysis not only confound interpretation of the results, but lead the authors to a conclusion that contradicts the data collected. [24] . The authors used a primary intention-to-treat analysis despite the high rate of violation of treatment allocation in the Combination Pain Trial and high degree of cross-over to treatment with RFN in the exercise-only group.
In this study, a significant proportion of patients with back pain for >10 years reported statistically significant improvements in pain in both the RFN and control groups. Of course, these findings could be related to a placebo effect, regression to the mean, or response attributable to involvement in a clinical trial, yet the magnitude of improvement was not the same between groups. As a consequence, it remains unclear why the authors interpreted these findings to represent no benefit when the RFN treatment groups exceeded the MCID threshold for treatment benefit while the control groups did not.
There are many potential sources of bias in this study, and the authors do not provide the necessary details for readers to understand their potential influence on the study results. Perhaps the most important involves details regarding exercise treatment. It is important to understand details about this treatment in both groups, both the groups' experience with the treatment before enrollment in the study and the type and quantity of exercise therapy provided during the study. Unfortunately, the authors did not provide this information. The same is true for co-interventions and psychological therapy provided to the treatment groups.
Despite the potential biases and the multiple technical shortcomings of the study, the RFN group's mean pain reduction at the primary end point of three months reached the threshold of clinically important improvement (NRS > 2) in all three trials, while this threshold was not reached in any of the exercise-only groups ( Figure 1) . Additionally, the proportion of participants that reported a successful outcome was significantly larger in the RFN group compared with the exerciseonly group in all three trials when using a GPR definition of treatment success. The proportion of participants with a successful outcome was also significantly larger in the RFN group compared with the exercise-only group in both the SIJ-Mediated Pain and Combination Pain Trials when using both >30% NRS reduction and a reduction of two of more points in NRS as the definition of treatment success. Regardless of these positive findings, the methodological flaws present in the Mint Trials preclude our ability to draw meaningful conclusions from the study data. This exemplifies why application of meticulous assessment according to EBM principles is vital when analyzing a publication.
In response to a request for clarification [3] , the authors have explained that the Mint Trials were only meant to test "patient selection and interventions as performed in Dutch daily practice," and thus do not apply to standard RFN selection and procedure technique as described in the SIS guidelines [3, 4] . This exchange underscores the importance of critical analysis, rooted in principles of EBM, in order to encourage transparency and ensure that appropriate conclusions are drawn from study data. 21) Do the authors draw appropriate conclusions from the study data?
APPENDIX B MINT TRIALS PROTOCOL FOR QUALITY CONTROL OF MEDIAL BRANCH NERVE RADIOFREQUENCY NEUROTOMY TECHNIQUE
Imaging: It is standard care, in performing the minimal interventional treatments as described under 5.1, to make and save radiographic images of the needle positions. Images saved in the Facet RCT will be submitted to an expert panel to assess correct needle placement. Retrospectively, we will submit all available (anonymized) images taken in the Facet RF RCT to a panel and have them judged twice, with a 1.5-month interval. Both times we will ask the panel to judge the images as "correct," "incorrect," or "unsure" needle placement.
Out of this, we want to determine an inter-and intraobserver reliability. If the reliability is high, we will determine whether "correct placement" indeed shows a higher pain reduction (NRS) after three months.
